Becton, Dickinson's divestment enhances focus, reduces leverage, funds buybacks, and unlocks value. Read more about the M&A and why I remain bullish on BDX.

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” second quarter 2025 investor ...

Heartland Advisors, an investment management company, released its “Heartland Mid Cap Value Fund” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The market rallied ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has submitted ...

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, beating ...

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) reached a new 52-week low on Wednesday after Morgan Stanley lowered their price target on the stock from $280.00 to $196.00. Morgan ...

BECTON, DICKINSON Hedge Fund Activity We have seen 686 institutional investors add shares of BECTON, DICKINSON stock to their portfolio, and 754 decrease their positions in their most recent quarter.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD ...

Before you invest in Becton, Dickinson and Company (BDX), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.

Becton, Dickinson and Company (NYSE: BDX) has near-perfection dividend credibility and has been a very solid dividend payer since 1962.